Baseline characteristics

Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib · Source last updated 2017-03-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

1. counts

   1. group Id

      BG000

      value

      80

   units

   Participants

groups

1. description

   Dovitinib (TKI) will be dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule.

   id

   BG000

   title

   TKI258

measures

1. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            spread

            11.62

            value

            58.3

   dispersion Type

   STANDARD_DEVIATION

   param Type

   MEAN

   title

   Age, Continuous

   unit Of Measure

   years

2. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            40

         title

         Female

      2. measurements

         1. group Id

            BG000

            value

            40

         title

         Male

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Sex: Female, Male

   unit Of Measure

   Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice